An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Idelalisib (Primary) ; Obinutuzumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms RemodelWM3
- 07 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Mar 2025.
- 07 Mar 2017 Planned primary completion date changed from 2 Jan 2017 to 1 Mar 2019.
- 03 Feb 2017 Status changed from not yet recruiting to recruiting.